Medifast CEO Buys $178,724 in Company Stock

The purchase represents a significant increase in the CEO's stake in the weight management company.

Mar. 28, 2026 at 8:27am

Got story updates? Submit your updates here. ›

Medifast Inc. (NYSE:MED) CEO Daniel Chard acquired 17,678 shares of the company's stock on March 20th, 2026 at an average price of $10.11 per share. The total value of the transaction was $178,724.58, increasing Chard's direct ownership to 17,678 shares valued at the same amount.

Why it matters

Insider purchases can be seen as a positive signal, indicating the CEO's confidence in the company's future prospects. This transaction represents a substantial increase in Chard's stake, potentially signaling his belief that Medifast's stock is undervalued at current levels.

The details

The purchase was disclosed in a filing with the Securities and Exchange Commission. Following the transaction, Chard now directly owns 17,678 shares of Medifast stock, valued at approximately $178,724.58. This represents a significant increase from his previous direct ownership position.

  • The stock purchase occurred on Friday, March 20th, 2026.

The players

Daniel Chard

The CEO of Medifast Inc., a health and wellness company specializing in weight-loss and nutrition products.

Medifast Inc.

A publicly traded company (NYSE:MED) that provides clinically supported weight-loss, weight-management, and healthy living products and services.

Got photos? Submit your photos here. ›

What they’re saying

“This represents a significant increase in my stake in Medifast, reflecting my confidence in the company's long-term growth potential.”

— Daniel Chard, CEO, Medifast Inc.

What’s next

Investors will be closely watching Medifast's stock performance in the coming weeks and months to see if the CEO's purchase signals a potential turnaround for the company.

The takeaway

Insider purchases, especially by a company's CEO, can be seen as a positive sign for investors. Chard's substantial investment in Medifast stock suggests he believes the company is undervalued and has a bright future ahead.